PGNX - CytoDyn's PRO 140: A Potential Victim Of Poor Clinical Development
So here it goes. I've written several articles, and preached to several wonderful choirs about some companies that I love. And the choirs sang beautifully. This time it's going to be a little different as I lay out a somewhat negative view on a company. To those invested in this stock, I apologize in advance, but sometimes a healthy dose of skepticism is good for the wallet. Seeking Alpha possesses a great community of empowered investors. But, biotech is tricky stuff because you can gain confidence around the 99 facets of a company that are